Category: Our News

Montréal, le 8 février 2023 – Axelys, la société de développement et de transfert des innovations issues de la recherche publique du Québec ainsi que les neuf (9) regroupements sectoriels de recherche industrielle (RSRI) composés de : CQDM, CQRDA, CRIAQ, CRIBIQ, CRITM, InnovÉÉ, MEDTEQ+, PRIMA Québec et Prompt, tous mandatés par le ministère de l’Économie, de l’Innovation…

Montreal, Quebec, February 2, 2023 – In celebration of World Cancer Day, CQDM is proud to announce the launch of a collaborative research project between Université de Montréal (UdeM), the Lady Davis Institute of the Jewish General Hospital and Defence Therapeutics, a Quebec-based biotechnology company specialized in the development of next-generation vaccines. The funding of…

Montreal, Quebec, December 8, 2022 – CQDM is pleased to announce the funding of a research study carried out at the Research Institute of the McGill University Health Centre (RI-MUHC) in collaboration with Divocco AI, a Montreal-based company focusing on perioperative care improvement using artificial intelligence (AI)-derived medical devices. The funding, totalling $1,057,502, was made…

Montreal (Quebec), November 24, 2022 – CQDM is proud to announce the funding of a research project led by Rosemary Bagot, Associate Professor at the Department of Psychology at McGill University. The project will be funded in collaboration with McGill University, Cubed Biotech Inc. (“Cubed Biotech”), as well as McGill University’s Healthy Brains, Healthy Lives…

MONTREAL, November 2, 2022 ─ The Canadian Cancer Society (CCS), CQDM, the Cole Foundation and Oncopole – pôle cancer du FRQS announced, today, grants of $8,485,132 to finance four research projects in Quebec, as part of the Pediatric Cancer Research Initiative. This funding, which will take place over three years, is part of a unique partnership…

ABOUT CQDM Since its creation, CQDM has raised nearly $190 million to fund the development of approximately 130 drugs addressing major health challenges, including cancer, neurodegenerative and metabolic diseases. CQDM is a biopharmaceutical research consortium whose mission is to fund the development of innovative tools and technologies that accelerate the development of safe and effective…

ABOUT CQDM Since its creation, CQDM has raised nearly $190 million to fund the development of approximately 130 drugs addressing major health challenges, including cancer, neurodegenerative and metabolic diseases. CQDM is a biopharmaceutical research consortium whose mission is to fund the development of innovative tools and technologies that accelerate the development of safe and effective…

MONTREAL, August 30, 2022 – CQDM is very pleased to announce the nomination of John Delaney and Jennifer Hamilton as members of the Scientific Advisory Board (SAB). The SAB is a key committee for CQDM as it provides strategic guidance regarding biopharmaceutical innovation and oversees the selection of projects funded by CQDM. John Delaney is…

ABOUT CQDM Since its creation, CQDM has raised nearly $190 million to fund the development of approximately 130 drugs addressing major health challenges, including cancer, neurodegenerative and metabolic diseases. CQDM is a biopharmaceutical research consortium whose mission is to fund the development of innovative tools and technologies that accelerate the development of safe and effective drugs. We…

Montreal, Quebec, July 12, 2022 ─ CQDM, the Quebec Breast Cancer Foundation and Theratechnologies today announced close to CAN $2 million of funding for a collaborative research project that aims to demonstrate the efficacy and safety of a potential innovative treatment for patients affected by metastatic cancer. This public-private partnership is made possible through a…